A conference call will be held today, March 6, by BSD Medical (2:00pm). Link:
http://www.investorcalendar.com/conferences/event.asp?ID=170614
Or, listen to the archived CC, later.
The main topic will be an update on the status of the MTX-180 product – currently the hot item.
The following are posts from today on the IV MB. These are mainly about some other of BSD M’s major products, which are nearing FDA approval. That is, several or more Phase 3 trials (or equivalent) are reporting very strong efficacy over present standard therapies. (Phase I is for safety, Phase 2 is for efficacy, Phase 3 is for efficacy compared to standard therapies and for longer term results). Already granted full approvals: BSD-500, TMX-1000, MTX-180. BSD Medical is the world leader in this major new cancer therapy regimen – widely applicable; not just another dangerous, sickening, limited-applicability drug.
Re the MTX-180: Impact in variation of portal venous bloodflow on the size of Radiofrequency and Microwave ablation lesions.
http://www.bsdmedical.com/brochures/Radiofrequency_Microwave_Ablation_Lesions.pdf
Proves the benefits of MicroWave ablation over RFA. [RFA is the present market leader]
Advanced Cervical Cancer, Hyperthermia and Radiation Abstract, BSD Medical (BSDM)
http://www.investorvillage.com/smbd.asp?mb=222&mn=3975&pt=msg&mid=12598014
From "The Lancet", ..."In a three year study conducted on advanced cervical cancer patients, survival rates increased from 27% to 51% with the addition of hyperthermia over radiation therapy alone"....
http://investor.bsdmedical.com/press-release/clinical-trials-and-research/bsd-medical-reports-clinical-study-demonstrates-threefold
--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today that published study results demonstrate improved rates of complete pathological tumor response (no evidence of viable tumor in primary tumor and lymph nodes) in advanced rectal cancer patients from the addition of hyperthermia, delivered using the BSD-2000 Hyperthermia System. The researchers also reported that hyperthermia may provide enough reduction in tumor size (downstaging) to allow an increased rate of sphincter preservation surgery (which can allow patients to maintain normal rectal function) in a subgroup of patients with rectal tumors located lower in the gastrointestinal tract. Hyperthermia was added to standard preoperative radiochemotherapy (combined radiotherapy and chemotherapy) for 61 patients, and results were retrospectively compared to 45 patients with locally advanced rectal cancer who were treated with standard preoperative radiochemotherapy alone.
The rate of complete pathological tumor response (pCR) was significantly higher in the patients receiving at least four hyperthermia treatments (22.5%), as compared to a rate of only 6.7% for patients receiving radiochemotherapy alone, and a rate of 4.7% for patients treated with radiochemotherapy and only one to three hyperthermia treatments (p=0.043). The researchers also noted that the pCR rate of 22.5% achieved from the addition of hyperthermia is higher than the pCR rate reported in most published presurgical radiochemotherapy studies, including studies utilizing multiple chemotherapy agents. Hyperthermia significantly increased the number of patients with tumors located within 8 cm of the anal verge who were able to have sphincter-sparing surgery: 57% in the hyperthermia group compared to only 35% in the group that did not receive hyperthermia (p=0.077). Sphincter-sparing surgery is expected to provide a dramatic improvement in quality of life for rectal cancer patients.
The study, “Pathological Complete Response and Sphincter-Sparing Surgery after Neoadjuvant Radiochemotherapy with Regional Hyperthermia for Locally Advanced Rectal Cancer Compared with Radiochemotherapy Alone,” was published in The International Journal of Hyperthermia by C. Schroeder, et al., from the Department of Radiation Oncology of the University of Tübingen (Tübingen), in Germany. Tübingen is one of Europe’s oldest and most prestigious universities and an international leader in medical research.
BSD Medical ABstract: Compare the occurence of surface burns , asynchronous multi-generator vs. MicroThermX synchronous phased array single generator
http://www.bsdmedical.com/brochures/MicroThermX_Surface_Burn_Abstract.pdf
Spells out the benefit of single generator MicroThermX sychronous phased array over currently used multi generator setups.... |
